


PRECISION ERA

Advanced Cancer Biotherapeutics
and
Personalised Treatment




Advanced Cancer Therapeutics



**Antibody-Drug Conjugate
(ADC)**




**Bi-Specific Antibody
(Immunotherapy)**



**Small Molecules
(Targeted Therapy)**

PainPoint in Preclinical Testing



Limitation

1. **MASK** Tumor Heterogeneity
2. **AVERAGE** Cell Responses
3. **OVERLOOK** Rare Subpopulation


Our Solution



WHAT if ?

We can isolate and culture every cell
one by one.

1 SINGLE-AI Plate



Single-AI Plate

Biocompatible Single Cell Isolation & Culture Plate

Features :

- 1.4 million Single Cell Analysis
- 96 drug testing
- 24 hours Turnover Time



Testing Platform for :

1. Tumor Heterogeneity
2. Single Cell Phenotype
3. Single Cell Drug Response
4. On/Off Targeted Mechanism

2

Artificial Intelligence

Every Cell has Different Responses



Biological Features

1. Proliferation Rate
2. Drug Response (Viability)
3. Morphology
4. On/Off-Target Mechanism



Single Cell Measurement

Neural Network Features

1. Single Cell Status (Nucleus)
2. Morphology <> Apoptosis
3. Morphology <> Drug Resistance
4. Morphology <> Biomarker

3 Automatic System



In-House Automation
(High Throughput Drug Screening)



FULL AUTOMATION

(Single Cell Analysis)

Single Cell Trapping



Drug Screening



Fluorescent Staining



Imaging



AI-Driven Analysis

DATASET CONSTRUCTION

Single Cell Functional AI Platform







SINGLE CELL RESOLUTION
DRIVE
THE NEXT BIOTECH WAVE

US\$11.66B
Cancer Cell Analysis
MARKET SIZE
(2024)

Application



Clinical - Predictive Diagnostics



R&D - Advanced Drug Development Pipeline





Business Model

Application : Cancer Cell Analysis Market



Strategic Business Model
"Razor and Blades"



Our Story



Chinese University
of Hong Kong

Award
HKD30,000 +
Grant
HKD800,000

(2021-2023)

CUHK PI Team
HKSTP Ideation Program

HKD150,000

(2023-2024)

CUHK TSSU Team
HKSTP INCU-BIO Program

HKD6,700,000

(2024-2028)

Service Providing
- APAC & US Market

Predicted Revenue
HKD3,000,000

(2026)



US\$2,000,000

For 15% Equity